Associations between persistence of bronchiectasis and clinical factors, CT factors, inflammation and infection are ... We also acknowledge the support of the Cystic Fibrosis Foundation, Australia.
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...
As per DelveInsight estimates, North America is anticipated to dominate the global airway clearance devices for cystic fibrosis market during the forecast period. In the device type segment of ...
The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs ...
The increasing need for airway clearance devices for cystic fibrosis is largely fueled by the rising prevalence of the disease, a growing number of genetic disorder cases, expanding R&D efforts ...
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
As per DelveInsight estimates, North America is anticipated to dominate the global airway clearance devices for cystic fibrosis market during the forecast period. In the device type segment of airway ...
He was voted top server in CT at one of the top restaurants. Here’s how he keeps customers happy. He was voted top server in CT at one of the top restaurants. Here's how he keeps customers happy.
The successful use of inhaled morphine to relieve dyspnea in a patient with end-stage cystic fibrosis (CF ... leading to chronic infections and bronchiectasis with resulting marked decline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback